8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 2, 2026·SEC
Material company update
Feb 25, 2026·SEC
Celldex Therapeutics, Inc.(CLDX)Earnings, Financials & Key Ratios
CLDX•NASDAQ
$39.93
Price updated Jul 7, 2026
AboutCelldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.Show more
- Revenue$2M-78.6%
- EBITDA-$284M-48.0%
- Net Income-$259M-63.9%
- EPS (Diluted)-3.90-59.2%
- Gross Margin100%+104.5%
- EBITDA Margin-18934.67%-592.7%
- Operating Margin-19160%-589.5%
- Net Margin-17253.33%-667.2%
- ROE-40.62%-51.3%
CLDX Price & Volume
Celldex Therapeutics, Inc. (CLDX) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Revenue Generation Capacity
Investment Thesis • Updated 2026Q1
VerdictNegative: The company's cash position of $35.7 million is inadequate to cover the quarterly burn rate exceeding $80 million
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical Trial Funding Gap
Key Thesis Takeaways
- Celldex Therapeutics remains in a high-risk, capital-intensive development phase, with its future valuation entirely dependent on the clinical success of barzolvolimab.
- The company faces a significant funding gap as R&D expenditures reached $75.4 million in 2025Q4, far exceeding its sporadic, non-commercial revenue streams.
- Investors should monitor the firm's ability to secure strategic partnerships or additional equity financing, as the current cash position of $35.7 million appears insufficient to sustain the ongoing, aggressive clinical trial burn rate.
Verdict Logic
signaling a high probability of near-term dilutive financing.
CLDX Growth Metrics
Celldex Therapeutics, Inc. (CLDX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-12.15%
5 Years-27.36%
3 Years-13.98%
TTM-89.15%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-58.62%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-58.15%
Return on Capital
10 Years-40.26%
5 Years-33.99%
3 Years-39.27%
Last Year-44.74%
CLDX Recent Earnings
Celldex Therapeutics, Inc. (CLDX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 4/12 qtrs (36%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$1.18-2.9%
$1.15
Rev
$15,000-98.1%
$795,364
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$1.22-22.0%
$1.00
Rev
$100,000-92.4%
$1M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$1.01-14.8%
$0.88
Rev
—
$2M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.85+1.2%
$0.86
Rev
$730,000-38.3%
$1M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.18vs $1.15-2.9% | $15,000vs $795,364-98.1% |
| Q1 2026 | Feb 25, 2026 | $1.22vs $1.00-22.0% | $100,000vs $1M-92.4% |
| Q4 2025 | Nov 10, 2025 | $1.01vs $0.88-14.8% | —vs $2M |
| Q3 2025 | Aug 7, 2025 | $0.85vs $0.86+1.2% | $730,000vs $1M-38.3% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Celldex Therapeutics, Inc. (CLDX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $39.93 | $2.66B | -10.24 | -78.63% | -17253.33% | -40.62% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $5.38 | $1.32B | -20.69 | 22.09% | -13.58% | -38.11% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $74.90 | $1.46B | -7.70 | -43.89% | -284.18% | -87% | — |
Compare CLDX vs Peers
Celldex Therapeutics, Inc. (CLDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CLDX SEC Filings & Documents
Celldex Therapeutics, Inc. (CLDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CLDX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CLDX Frequently Asked Questions
Celldex Therapeutics, Inc. (CLDX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Celldex Therapeutics, Inc.'s revenue?
Celldex Therapeutics, Inc. (CLDX) reported $0.8M in revenue for fiscal year 2025. This represents a 25% decrease from $1.1M in 1996.
How fast is Celldex Therapeutics, Inc. growing?
Celldex Therapeutics, Inc. (CLDX) saw revenue decline by 78.6% over the past year.
Is CLDX profitable?
Celldex Therapeutics, Inc. (CLDX) reported a net loss of $283.7M for fiscal year 2025.
Dividend & Returns
What is CLDX's return on equity?
Celldex Therapeutics, Inc. (CLDX) has a return on equity (ROE) of -40.6%. Negative ROE indicates the company is unprofitable.
What is Celldex Therapeutics, Inc.'s free cash flow?
Celldex Therapeutics, Inc. (CLDX) had negative free cash flow of $226.0M in fiscal year 2025, likely due to heavy capital investments.